Effects of dapagliflozin in the progression of atherosclerosis in patients with type 2 diabetes: a meta-analysis of randomized controlled trials.

Diabetol Metab Syndr · 2022 · PMC8908556 · PMID 35272683

Europe PMC DOI

hedged sentences

0.0000

closest p · 0.0× alpha

0.0000

boldest claim

The sentences

extremely significantP < 0.00001actually significant

Not only that, the comprehensive effects revealed that the TC changes relative to baseline further became an extremely significant difference in both groups [MD = 3.34; 95% CI (1.88, 4.79); P < 0.00001].

also in 7,787 other papers

highly significantP < 0.00001actually significant

The pooled analysis resulted in a highly significant difference in LDL-C changes relative to baseline between dapagliflozin and placebo [MD = 4.24; 95% CI (2.83, 5.64); P < 0.00001], with low heterogeneity (I 2 = 0%).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.